GlassScriptPhysician profile
Katherine Holzman
NPI 1255778791
$2,676.71
in general payments reported to CMS, 2019-2025
27 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $108 · 2021: $26.79 · 2022: $269 · 2023: $851 · 2024: $785 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.16 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $304.49 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $293.07 | 2019-2025 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $168.49 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $164.90 | 2023-2025 | |
| Abbott Laboratories | $143.03 | 2023-2024 | Jot Dx, Freestyle Libre 3, Afinion 2 |
| Exact Sciences Corporation | $139.55 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $131.20 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $121.31 | 2023-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.67 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $79.15 | 2023-2024 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $76.36 | 2023-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $67.54 | 2020-2025 | Contrave, Nexletol |
| Sanofi Pasteur INC. | $55.45 | 2023 | |
| Novartis Pharmaceuticals Corporation | $48.78 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $39.64 | 2020-2024 | Heplisav-B |
| Averitas Pharma INC. | $39.44 | 2025 | Qutenza |
| Merck Sharp & Dohme LLC | $32.01 | 2022-2025 | Gardasil 9, Capvaxive |
| Dexcom, INC. | $29.25 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $23.03 | 2019 | |
| Allergan, INC. | $21.57 | 2020 | |
| Shire North American Group INC | $20.89 | 2019 | |
| Esperion Therapeutics, INC. | $20.83 | 2024 | Nexletol |
| Paratek Pharmaceuticals, INC. | $17.99 | 2025 | Nuzyra |
| Astellas Pharma US INC | $16.24 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $15.31 | 2024 | Livalo |
| Genentech USA, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Holzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.